Loring Wolcott & Coolidge Fiduciary Advisors LLP Crispr Therapeutics Ag Transaction History
Loring Wolcott & Coolidge Fiduciary Advisors LLP
- $11.1 Billion
- Q3 2024
A detailed history of Loring Wolcott & Coolidge Fiduciary Advisors LLP transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Loring Wolcott & Coolidge Fiduciary Advisors LLP holds 990 shares of CRSP stock, worth $51,361. This represents 0.0% of its overall portfolio holdings.
Number of Shares
990
Previous 990
-0.0%
Holding current value
$51,361
Previous $53,000
13.21%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding CRSP
# of Institutions
499Shares Held
56.8MCall Options Held
1.7MPut Options Held
1.8M-
Capital International Investors Los Angeles, CA7.87MShares$408 Million0.09% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl7.5MShares$389 Million3.35% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.2.97MShares$154 Million0.1% of portfolio
-
Nikko Asset Management Americas, Inc.2.97MShares$154 Million1.61% of portfolio
-
Black Rock Inc. New York, NY2.78MShares$144 Million0.0% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $4.05B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....